Shares of The Medicines Company (NASDAQ:MDCO) have been assigned a consensus rating of “Buy” from the ten research firms that are presently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $45.50.
A number of research firms have commented on MDCO. Zacks Investment Research upgraded shares of The Medicines from a “sell” rating to a “hold” rating in a research report on Monday, December 31st. BidaskClub upgraded shares of The Medicines from a “sell” rating to a “hold” rating in a research report on Saturday, February 2nd. Oppenheimer set a $50.00 price target on shares of The Medicines and gave the company a “buy” rating in a research report on Friday, November 9th. Cowen set a $46.00 price target on shares of The Medicines and gave the company a “buy” rating in a research report on Sunday, November 11th. Finally, Wolfe Research began coverage on shares of The Medicines in a research report on Friday, December 14th. They issued an “outperform” rating on the stock.
NASDAQ:MDCO opened at $23.78 on Wednesday. The Medicines has a 12 month low of $16.69 and a 12 month high of $41.57. The company has a quick ratio of 2.40, a current ratio of 2.41 and a debt-to-equity ratio of 31.23.
The Medicines (NASDAQ:MDCO) last released its quarterly earnings results on Thursday, November 8th. The company reported ($0.70) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.13). The firm had revenue of ($3.30) million during the quarter, compared to analyst estimates of $1.88 million. The Medicines had a negative net margin of 668.93% and a negative return on equity of 1,477.75%. The Medicines’s quarterly revenue was down 141.8% on a year-over-year basis. During the same quarter last year, the firm earned ($1.19) earnings per share. Equities analysts anticipate that The Medicines will post -2.91 earnings per share for the current year.
In related news, Director Alexander J. Denner bought 819,000 shares of the company’s stock in a transaction on Friday, December 14th. The stock was bought at an average cost of $20.26 per share, with a total value of $16,592,940.00. Following the completion of the purchase, the director now owns 10,429 shares in the company, valued at approximately $211,291.54. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Christopher T. Cox bought 113,500 shares of the company’s stock in a transaction on Thursday, December 20th. The stock was bought at an average cost of $17.70 per share, with a total value of $2,008,950.00. Following the completion of the purchase, the executive vice president now owns 60,308 shares of the company’s stock, valued at approximately $1,067,451.60. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 1,052,589 shares of company stock valued at $20,865,236. Insiders own 10.29% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in MDCO. Iridian Asset Management LLC CT raised its stake in shares of The Medicines by 75.4% in the fourth quarter. Iridian Asset Management LLC CT now owns 3,296,816 shares of the company’s stock worth $63,101,000 after acquiring an additional 1,417,229 shares during the last quarter. Westfield Capital Management Co. LP raised its stake in shares of The Medicines by 21.6% during the fourth quarter. Westfield Capital Management Co. LP now owns 4,604,719 shares of the company’s stock worth $88,134,000 after buying an additional 817,508 shares during the last quarter. Oregon Public Employees Retirement Fund bought a new stake in shares of The Medicines during the fourth quarter worth approximately $25,000. University of Notre Dame DU Lac raised its stake in shares of The Medicines by 248.0% during the third quarter. University of Notre Dame DU Lac now owns 297,859 shares of the company’s stock worth $8,909,000 after buying an additional 212,277 shares during the last quarter. Finally, Federated Investors Inc. PA bought a new stake in shares of The Medicines during the third quarter worth approximately $6,275,000.
The Medicines Company Profile
The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.
Featured Story: What is an SEC Filing?
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.